Viewing Study NCT05603156

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:35 PM
Ignite Modification Date: 2026-05-30 @ 4:30 PM
Study NCT ID: NCT05603156
Status: UNKNOWN
Last Update Posted: 2022-11-02
First Post: 2022-10-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ph+ ALL View
None Bone Marrow Transplant View
None Minimal Residual Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ph+ALL View
None HSCT View
None MRD persistent positive View
None Inotuzumab View
None tyrosine kinase inhibitor View